CTXR
Income statement / Annual
Last year (2023), Citius Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Citius Pharmaceuticals, Inc.'s net income was -$32.54 M.
See Citius Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
09/30/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$194,316.00 |
$179,677.00 |
$164,868.00 |
$152,364.00 |
$893.00 |
$1,753.00 |
$2,632.00 |
$1,343.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$194,316.00 |
-$179,677.00 |
-$164,868.00 |
-$152,364.00 |
-$893.00 |
-$1,753.00 |
-$2,632.00 |
-$1,343.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$14.82 M
|
$17.66 M
|
$12.24 M
|
$8.81 M
|
$8.60 M
|
$6.56 M
|
$2.94 M
|
$2.93 M
|
$1.80 M
|
$437,971.00
|
| General & Administrative
Expenses |
$21.91 M
|
$15.66 M
|
$11.29 M
|
$8.90 M
|
$7.00 M
|
$7.23 M
|
$7.05 M
|
$4.52 M
|
$1.43 M
|
$715,025.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$21.91 M
|
$15.66 M
|
$11.29 M
|
$8.90 M
|
$7.00 M
|
$7.23 M
|
$7.05 M
|
$4.52 M
|
$1.43 M
|
$715,025.00
|
| Other Expenses |
-$0.00 |
$1.45 M |
$59,917.00 |
$110,207.00 |
$715,983.00 |
$1.27 M |
$732,151.00 |
$732,151.00 |
$486,271.00 |
$0.00 |
| Operating Expenses |
$36.73 M |
$33.32 M |
$23.53 M |
$17.71 M |
$15.60 M |
$13.79 M |
$9.99 M |
$7.45 M |
$3.23 M |
$1.14 M |
| Cost And Expenses |
$36.73 M |
$33.32 M |
$23.53 M |
$17.71 M |
$15.60 M |
$13.79 M |
$9.99 M |
$7.45 M |
$3.23 M |
$1.14 M |
| Interest Income |
$1.18 M |
$251,399.00 |
$261,825.00 |
$68,066.00 |
$52,660.00 |
$0.00 |
$806.00 |
$806.00 |
$3,066.00 |
$0.00 |
| Interest Expense |
$0.00 |
$251,399.00 |
$10,839.00 |
$15,673.00 |
$16,443.00 |
$15,838.00 |
$850,789.00 |
$8,994.00 |
$7,500.00 |
$0.00 |
| Depreciation &
Amortization |
$194,316.00
|
$179,677.00
|
$164,868.00
|
$152,364.00
|
$893.00
|
$1,753.00
|
$2,632.00
|
$1,343.00
|
$3,066.00
|
$1.15 M
|
| EBITDA |
-$36.73 M
|
-$32.88 M
|
-$22.88 M
|
-$17.38 M
|
-$15.54 M
|
-$13.79 M
|
-$9.98 M
|
-$7.45 M
|
-$3.23 M
|
$0.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$4.77 M
|
$251,399.00
|
$477,460.00
|
$162,600.00
|
$36,217.00
|
$1.25 M
|
-$398,642.00
|
-$846,407.00
|
$327,661.00
|
$171,820.00
|
| Income Before Tax |
-$31.97 M |
-$33.06 M |
-$23.05 M |
-$17.55 M |
-$15.56 M |
-$12.54 M |
-$10.38 M |
-$8.30 M |
-$2.90 M |
-$1.27 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$576,000.00 |
$576,000.00 |
$70,756.00 |
$125,880.00 |
$16,443.00 |
$1.28 M |
$850,789.00 |
$8,994.00 |
$4,434.00 |
-$119,145.00 |
| Net Income |
-$32.54 M |
-$33.64 M |
-$23.13 M |
-$17.67 M |
-$15.58 M |
-$12.54 M |
-$10.38 M |
-$8.30 M |
-$2.90 M |
-$1.27 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.22 |
-0.23 |
-0.21 |
-0.45 |
-0.77 |
-1.17 |
-1.89 |
-2.29 |
-1.37 |
0 |
| EPS Diluted |
-0.22 |
-0.23 |
-0.21 |
-0.45 |
-0.77 |
-1.17 |
-1.89 |
-2.29 |
-1.37 |
0 |
| Weighted Average Shares
Out |
$151.29 M
|
$146.08 M
|
$108.60 M
|
$39.17 M
|
$20.16 M
|
$10.73 M
|
$5.48 M
|
$3.62 M
|
$2.12 M
|
$0.00
|
| Weighted Average Shares
Out Diluted |
$151.29 M
|
$146.08 M
|
$108.60 M
|
$39.17 M
|
$20.16 M
|
$10.73 M
|
$5.48 M
|
$3.62 M
|
$2.12 M
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
